Diligence memo · auto-generated · as of July 2, 2026

Knopp Neurosciences Inc.

Knopp Neurosciences Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Knopp Neurosciences Inc. operates in Biotechnology, based in PITTSBURGH.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Knopp Neurosciences Inc. has raised $73M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $60M on 2010-08-23.

Most recent recorded round closed around 2010-08-23.

Valuation (modeled)modeled

Provath models Knopp Neurosciences Inc. at approximately $2.5B (range $186M–$6.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.23× the median modeled value of Series C Biotechnology companies in 2010–2012 (19 peers) — value vs value, same stage and era. Within the normal band (123% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 15.9 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 13.6× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 87% of Biotechnology peers (4293 compared).

Modeled value ranks above 96% of those peers.

Closest niche peers: Insmed Inc, Infinity Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Relypsa Inc, Nevro Corp.

Peoplefiled

10 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.